Abbvie Inc (ABBV)

$256.12 -4.09 (-1.57%)
Market Cap 462.41B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 23.92
Forward PE 18.50
Profit Margin 6.91%
Debt to Equity Ratio -12.03
Volume 2,258,713
Avg Vol 6,484,846
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 54%
Beta 0.29
Analysts Strong Sell
Price Target $276.37

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
Pope_of_Profit
Pope_of_Profit Sep. 4 at 6:58 PM
$ABBV needs to go below (a)
0 · Reply
prismmarketview
prismmarketview Sep. 4 at 2:54 PM
$ABBV AbbVie’s investigational etentamig met dual primary endpoints in the Phase 3 CERVINO study in triple-class-exposed relapsed/refractory multiple myeloma. The therapy delivered a 74% objective response rate and reduced the risk of progression or death by 60% versus standard available treatments. https://prismmarketview.com/abbvies-etentamig-shows-strong-results-in-phase-3-blood-cancer-study/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 1:25 PM
$SLS $ABBV $BMY the Market will reopen Tuesday after a Long Weekend - it'll be 120 Days Since the 78th Event. At some point we will get the 80th Event PR and the Share Price will Launch .. .. $25 / $28 is my Estimate +$5B Mcap - and it'll continue Climbing til we see the P3 Top Line and then its Launch Time - ballistic Verticality. and the funny thing is, when we get the 80th EVENT - any day now - there'll be Many Idiots on this board posting about how they're surprised, and they should have bought more shares - watch. People are DUMB AS F. 120 Days - Events were occurring 1 Per Month from the 60th to 78th.
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 1:02 PM
$SLS $MRNA 2025 REGAL Interim Analysis was announced -- 60 Events. $.9 / $1.0 share price at the time - Jumped to $1.70 Including 50M shares of Dilution. Mcap increased 3x ... in a week after the Interim. Added Cash / warrants.... • the Share PRICE Started Climbing - along with funds invested, cash on hand, BAT Phase 3 Trial Failures, Market cap up more than the Share Price. • ALL SINCE THE IDMC UNBLINDED ACTUAL PHASE 3 MOS and Confirmatory Immune Response DATA • that told Smarter Money than most of US -- GPS is reason we are seeing Miraculous Extended Survival. $ABBV $BMY who own Aza VEN - Know ... and many many others Holding the 200M share float. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 12:59 PM
$SLS $ABBV $BMY the Market will reopen Tuesday after a Long Weekend - it'll be 120 Days Since the 78th Event. At some point we will get the 80th Event PR and the Share Price will Launch .. .. $25 / $28 is my Estimate +$5B Mcap - and it'll continue Climbing til we see the P3 Top Line and then its Launch Time - ballistic Verticality. and the funny thing is, when we get the 80th EVENT - any day now - there'll be Many Idiots on this board posting about how they're surprised, and they should have bought more shares - watch. People are DUMB AS F. 120 Days - Events were occurring 1 Per Month from the 60th to 78th.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 8:12 AM
$SLS $ABBV $BMY the Market will reopen Tuesday after a Long Weekend - it'll be 120 Days Since the 78th Event. At some point we will get the 80th Event PR and the Share Price will Launch .. just like the last times. .. $25 / $28 is my Estimate +$5B Mcap - and it'll continue Climbing til we see the P3 Top Line and then its Launch Time - ballistic Verticality. and the funny thing is, when we get the 80th EVENT - any day now - there'll be Many Idiots on this board posting about how they're surprised, and they should have bought more shares - watch. People are DUMB AS F. 120 Days - Events were occurring 1 Per Month from the 60th to 78th.
1 · Reply
Techdamentals
Techdamentals Sep. 4 at 3:31 AM
$ABBV at a 52-week high. $260 now. Find out what it is actually worth 👇 https://techdamentals.com/v/ABBV?ref=st
0 · Reply
DidYouReadThis
DidYouReadThis Sep. 4 at 12:27 AM
$ABBV
0 · Reply
HedgeFollow
HedgeFollow Sep. 3 at 10:54 PM
. 🔍 𝗖𝗜𝗧𝗔𝗗𝗘𝗟 13𝗙 𝗷𝘂𝘀𝘁 𝗥𝗘𝗟𝗘𝗔𝗦𝗘𝗗 🔎 5-star Hedge Fund Manager Ken Griffin just filed his 13F for Q2. 𝘔𝘰𝘴𝘵 𝘯𝘰𝘵𝘢𝘣𝘭𝘦 𝘱𝘰𝘳𝘵𝘧𝘰𝘭𝘪𝘰 𝘤𝘩𝘢𝘯𝘨𝘦𝘴: 𝗡𝗲𝘄 𝗟𝗔𝗥𝗚𝗘 𝗕𝘂𝘆𝘀: $SPCX 𝗔𝗱𝗱𝗲𝗱 20-40% 𝗺𝗼𝗿𝗲: $NOW 𝗧𝗥𝗜𝗣𝗟𝗘𝗗 position: $LLY Heavily 𝗕𝗢𝗢𝗦𝗧𝗘𝗗: $ABT & $ABBV 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 80%: NVDA, SNDK & MU 𝗦𝗢𝗟𝗗 out: Astera Labs People don't like them but Citadel's 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗶𝘀 𝗨𝗣 93.26% in the past 3 years. Watch what they do. Source: hedgefollow.com/funds/Citadel+Advisors
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 3 at 9:15 PM
$SLS $ABBV $BMY Chart Since the IDMC UNBLINDED ACTUAL P3 DATA - says it all. "Select blinded data revealed that fewer than 50% of enrolled patients were confirmed deceased approximately 10 months after enrollment and an approximate median follow-up of 13.5 months (range, 1-36+). Additionally, pooled median survival appeared to be at least 13.5 months compared with an expected 6-month survival in a similar patient population. An additional blinded analysis of early immune response in a random sample of patients showed an 80% GPS-specific immune response rate. “The interim results represent a major step forward in the treatment of AML, offering hope for patients in remission,” Yair Levy, MD, director of Hematologic Malignancies Research at Texas Oncology Baylor University Medical Center. “I am very hopeful that we will see a new standard of care in treating [patients with] AML based on the outcomes we have observed in previous GPS trials.” open-label REGAL trial https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
Latest News on ABBV
AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

2026-09-03T13:25:47.000Z - 1 day ago

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

AbbVie's blood cancer drug meets late-stage trial goals

Sep 3, 2026, 9:22 AM EDT - 1 day ago

AbbVie's blood cancer drug meets late-stage trial goals

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

Sep 3, 2026, 9:15 AM EDT - 1 day ago

AbbVie Announces Positive Topline Results from the Phase 3 CERVINO Trial Showing Etentamig Significantly Improved Response Rate and Progression-Free Survival in Patients with Relapsed/Refractory Multiple Myeloma

AbbVie completes acquisition of Apogee for $135.11 per share in cash

2026-09-03T12:41:00.000Z - 1 day ago

AbbVie completes acquisition of Apogee for $135.11 per share in cash

APGE

AbbVie Completes Acquisition of Apogee Therapeutics

Sep 3, 2026, 8:34 AM EDT - 1 day ago

AbbVie Completes Acquisition of Apogee Therapeutics

APGE

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

Sep 3, 2026, 8:05 AM EDT - 1 day ago

AbbVie to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

AbbVie’s Allergan expands SkinMedica’s portfolio with Barrier Calming Cream

2026-09-01T12:15:42.000Z - 3 days ago

AbbVie’s Allergan expands SkinMedica’s portfolio with Barrier Calming Cream

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

Sep 1, 2026, 8:05 AM EDT - 3 days ago

SkinMedica® Adds Barrier Calming Cream to its Collection of Regenerative Skincare Offerings

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

Aug 31, 2026, 8:00 AM EDT - 4 days ago

AbbVie to Present at the Wells Fargo 21st Annual Healthcare Conference

AbbVie submits Skyrizi application to the EMA

2026-08-27T09:21:03.000Z - 8 days ago

AbbVie submits Skyrizi application to the EMA

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Aug 27, 2026, 2:00 AM EDT - 8 days ago

AbbVie Submits Regulatory Application to EMA for SKYRIZI® (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

Emily Field: Large pharma companies are going to continue looking at biotech

Aug 24, 2026, 10:45 AM EDT - 11 days ago

Emily Field: Large pharma companies are going to continue looking at biotech

IBB MRK MRNA XLV

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

Aug 21, 2026, 7:45 AM EDT - 14 days ago

AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline

AbbVie price target raised to $303 from $298 at Piper Sandler

2026-08-20T10:55:24.000Z - 15 days ago

AbbVie price target raised to $303 from $298 at Piper Sandler

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

Aug 18, 2026, 8:00 AM EDT - 17 days ago

AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support

AbbVie price target raised to $300 from $295 at Wells Fargo

2026-08-17T10:55:57.000Z - 18 days ago

AbbVie price target raised to $300 from $295 at Wells Fargo

AbbVie upgraded to Outperform from Peer Perform at Wolfe Research

2026-08-17T08:29:38.000Z - 18 days ago

AbbVie upgraded to Outperform from Peer Perform at Wolfe Research

Expert explains why healthcare is a top-performing sector

Aug 13, 2026, 11:15 PM EDT - 21 days ago

Expert explains why healthcare is a top-performing sector

AMGN BIIB GILD JNJ LLY MRK UNH

AbbVie price target raised to $260 from $246 at Evercore ISI

2026-08-10T12:16:02.000Z - 25 days ago

AbbVie price target raised to $260 from $246 at Evercore ISI

AbbVie upgraded to Buy from Hold at Erste Group

2026-08-05T14:36:14.000Z - 4 weeks ago

AbbVie upgraded to Buy from Hold at Erste Group

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

2026-08-04T13:35:25.000Z - 4 weeks ago

AbbVie’s Botox Cosmetic sBLA for masseter muscle prominence accepted by FDA

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

2026-08-04T12:10:59.000Z - 4 weeks ago

AbbVie’s Allergan Aesthetics receives FDA approval of sBLA for Botox Cosmetic

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

Aug 4, 2026, 8:00 AM EDT - 4 weeks ago

Allergan Aesthetics Announces U.S. FDA Acceptance of Supplemental Biologics License Application for BOTOX® Cosmetic for Masseter Muscle Prominence

AbbVie price target raised to $288 from $261 at Guggenheim

2026-08-04T10:52:04.000Z - 4 weeks ago

AbbVie price target raised to $288 from $261 at Guggenheim

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

2026-08-03T12:42:03.000Z - 4 weeks ago

AbbVie price target raised to $285 from $265 at Cantor Fitzgerald

AbbVie price target raised to $296 from $278 at Morgan Stanley

2026-08-03T12:06:31.000Z - 4 weeks ago

AbbVie price target raised to $296 from $278 at Morgan Stanley

AbbVie price target raised to $290 from $282 at Canaccord

2026-08-03T11:06:04.000Z - 4 weeks ago

AbbVie price target raised to $290 from $282 at Canaccord

AbbVie Earnings Call Transcript: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Earnings Call Transcript: Q2 2026

AbbVie Earnings release: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Earnings release: Q2 2026

AbbVie Quarterly report: Q2 2026

Jul 31, 2026, 9:00 AM EDT - 5 weeks ago

AbbVie Quarterly report: Q2 2026

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

Jul 31, 2026, 8:36 AM EDT - 5 weeks ago

AbbVie Lowers Outlook to Account for Acquisition as Profit Jumps

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

Jul 31, 2026, 8:31 AM EDT - 5 weeks ago

AbbVie Bought Apogee to Strengthen Its Portfolio. Now It's Cutting Earnings Guidance.

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

Jul 31, 2026, 7:50 AM EDT - 5 weeks ago

AbbVie trims 2026 profit forecast on Apogee buy, beats second-quarter estimates

AbbVie Reports Second-Quarter 2026 Financial Results

Jul 31, 2026, 7:47 AM EDT - 5 weeks ago

AbbVie Reports Second-Quarter 2026 Financial Results

JUVÉDERM® Day Returns to U.S. on August 19

Jul 30, 2026, 8:00 AM EDT - 5 weeks ago

JUVÉDERM® Day Returns to U.S. on August 19

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jul 29, 2026, 3:00 AM EDT - 5 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Jul 29, 2026, 3:00 AM EDT - 5 weeks ago

AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Jul 23, 2026, 4:00 PM EDT - 6 weeks ago

Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

GMAB

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jul 17, 2026, 8:00 AM EDT - 7 weeks ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE), for use in Europe: the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Jul 14, 2026, 8:05 AM EDT - 7 weeks ago

SkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Development

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

Jul 13, 2026, 5:06 PM EDT - 7 weeks ago

Big Pharma's $300 Billion Patent Problem Fuels Biotech Deals

APGE SBIO

Buy these quality, low-stress stocks for the summer, says Jefferies

Jul 7, 2026, 11:45 AM EDT - 1 month ago

Buy these quality, low-stress stocks for the summer, says Jefferies

AXP HD LOW MCD NFLX PEP PG

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

Jul 6, 2026, 1:45 PM EDT - 2 months ago

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

US House committee opens investigation into Merck, AbbVie China drug trials

Jun 30, 2026, 6:02 AM EDT - 2 months ago

US House committee opens investigation into Merck, AbbVie China drug trials

MRK

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jun 29, 2026, 4:15 PM EDT - 2 months ago

AbbVie Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

Jun 29, 2026, 3:10 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

Jun 29, 2026, 3:00 AM EDT - 2 months ago

AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Jun 26, 2026, 4:50 PM EDT - 2 months ago

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

Healthcare stocks have become a haven for investors ditching tech

Jun 26, 2026, 2:39 PM EDT - 2 months ago

Healthcare stocks have become a haven for investors ditching tech

ABSI APGE JNJ LLY MRNA SNY XBI

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

Jun 26, 2026, 8:00 AM EDT - 2 months ago

AbbVie to Host Second-Quarter 2026 Earnings Conference Call

AbbVie's $11 Billion Immunology Bet

Jun 24, 2026, 12:51 PM EDT - 2 months ago

AbbVie's $11 Billion Immunology Bet

APGE

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Jun 24, 2026, 8:00 AM EDT - 2 months ago

BOTOX® Cosmetic (onabotulinumtoxinA) Introduces The Confidence Collective's Entrepreneur Class of 2026

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

Jun 23, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics receives approval for Boey® (trenibotulinumtoxinE) in Canada, the first and only rapid-onset, short-duration neurotoxin for the temporary improvement of frown lines in adult patients

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

Jun 23, 2026, 5:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of MAVIRET® (Glecaprevir/Pibrentasvir) for People with Acute Hepatitis C Virus Infection

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

Jun 23, 2026, 3:00 AM EDT - 2 months ago

AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis

EC

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

Jun 22, 2026, 10:30 AM EDT - 2 months ago

Monday's Morning Movers: MU & Anthropic Partnership, New CRDO Bull, ABBV Buys APGE

CRDO MU APGE

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

Jun 22, 2026, 10:15 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion

APGE

AbbVie Transcript: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Transcript: M&A announcement

AbbVie Slides: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Slides: M&A announcement

AbbVie Press release: M&A announcement

Jun 22, 2026, 9:00 AM EDT - 2 months ago

AbbVie Press release: M&A announcement

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

Jun 22, 2026, 7:42 AM EDT - 2 months ago

AbbVie to Buy Apogee Therapeutics for $10.9 Billion in Cash

APGE

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

Jun 22, 2026, 7:06 AM EDT - 2 months ago

Apogee Therapeutics Stock Soars. It's Being Bought by AbbVie for $10.9 Billion.

APGE

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

Jun 22, 2026, 7:04 AM EDT - 2 months ago

AbbVie strikes $10.9 billion deal for Apogee Therapeutics

APGE

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

Jun 22, 2026, 7:00 AM EDT - 2 months ago

AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio

APGE

AbbVie would gain an experimental eczema drug by buying biotech: report

Jun 20, 2026, 12:11 PM EDT - 2 months ago

AbbVie would gain an experimental eczema drug by buying biotech: report

APGE

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

Jun 19, 2026, 11:17 AM EDT - 2 months ago

AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports

APGE

AbbVie Declares Quarterly Dividend

Jun 18, 2026, 4:05 PM EDT - 2 months ago

AbbVie Declares Quarterly Dividend

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

Jun 16, 2026, 8:00 AM EDT - 2 months ago

Allergan Aesthetics Receives U.S. FDA Approval for SKINVIVE by JUVÉDERM® for the Improvement of Neck Appearance

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Jun 12, 2026, 3:00 AM EDT - 2 months ago

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

Pope_of_Profit
Pope_of_Profit Sep. 4 at 6:58 PM
$ABBV needs to go below (a)
0 · Reply
prismmarketview
prismmarketview Sep. 4 at 2:54 PM
$ABBV AbbVie’s investigational etentamig met dual primary endpoints in the Phase 3 CERVINO study in triple-class-exposed relapsed/refractory multiple myeloma. The therapy delivered a 74% objective response rate and reduced the risk of progression or death by 60% versus standard available treatments. https://prismmarketview.com/abbvies-etentamig-shows-strong-results-in-phase-3-blood-cancer-study/
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 1:25 PM
$SLS $ABBV $BMY the Market will reopen Tuesday after a Long Weekend - it'll be 120 Days Since the 78th Event. At some point we will get the 80th Event PR and the Share Price will Launch .. .. $25 / $28 is my Estimate +$5B Mcap - and it'll continue Climbing til we see the P3 Top Line and then its Launch Time - ballistic Verticality. and the funny thing is, when we get the 80th EVENT - any day now - there'll be Many Idiots on this board posting about how they're surprised, and they should have bought more shares - watch. People are DUMB AS F. 120 Days - Events were occurring 1 Per Month from the 60th to 78th.
2 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 1:02 PM
$SLS $MRNA 2025 REGAL Interim Analysis was announced -- 60 Events. $.9 / $1.0 share price at the time - Jumped to $1.70 Including 50M shares of Dilution. Mcap increased 3x ... in a week after the Interim. Added Cash / warrants.... • the Share PRICE Started Climbing - along with funds invested, cash on hand, BAT Phase 3 Trial Failures, Market cap up more than the Share Price. • ALL SINCE THE IDMC UNBLINDED ACTUAL PHASE 3 MOS and Confirmatory Immune Response DATA • that told Smarter Money than most of US -- GPS is reason we are seeing Miraculous Extended Survival. $ABBV $BMY who own Aza VEN - Know ... and many many others Holding the 200M share float. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 12:59 PM
$SLS $ABBV $BMY the Market will reopen Tuesday after a Long Weekend - it'll be 120 Days Since the 78th Event. At some point we will get the 80th Event PR and the Share Price will Launch .. .. $25 / $28 is my Estimate +$5B Mcap - and it'll continue Climbing til we see the P3 Top Line and then its Launch Time - ballistic Verticality. and the funny thing is, when we get the 80th EVENT - any day now - there'll be Many Idiots on this board posting about how they're surprised, and they should have bought more shares - watch. People are DUMB AS F. 120 Days - Events were occurring 1 Per Month from the 60th to 78th.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 4 at 8:12 AM
$SLS $ABBV $BMY the Market will reopen Tuesday after a Long Weekend - it'll be 120 Days Since the 78th Event. At some point we will get the 80th Event PR and the Share Price will Launch .. just like the last times. .. $25 / $28 is my Estimate +$5B Mcap - and it'll continue Climbing til we see the P3 Top Line and then its Launch Time - ballistic Verticality. and the funny thing is, when we get the 80th EVENT - any day now - there'll be Many Idiots on this board posting about how they're surprised, and they should have bought more shares - watch. People are DUMB AS F. 120 Days - Events were occurring 1 Per Month from the 60th to 78th.
1 · Reply
Techdamentals
Techdamentals Sep. 4 at 3:31 AM
$ABBV at a 52-week high. $260 now. Find out what it is actually worth 👇 https://techdamentals.com/v/ABBV?ref=st
0 · Reply
DidYouReadThis
DidYouReadThis Sep. 4 at 12:27 AM
$ABBV
0 · Reply
HedgeFollow
HedgeFollow Sep. 3 at 10:54 PM
. 🔍 𝗖𝗜𝗧𝗔𝗗𝗘𝗟 13𝗙 𝗷𝘂𝘀𝘁 𝗥𝗘𝗟𝗘𝗔𝗦𝗘𝗗 🔎 5-star Hedge Fund Manager Ken Griffin just filed his 13F for Q2. 𝘔𝘰𝘴𝘵 𝘯𝘰𝘵𝘢𝘣𝘭𝘦 𝘱𝘰𝘳𝘵𝘧𝘰𝘭𝘪𝘰 𝘤𝘩𝘢𝘯𝘨𝘦𝘴: 𝗡𝗲𝘄 𝗟𝗔𝗥𝗚𝗘 𝗕𝘂𝘆𝘀: $SPCX 𝗔𝗱𝗱𝗲𝗱 20-40% 𝗺𝗼𝗿𝗲: $NOW 𝗧𝗥𝗜𝗣𝗟𝗘𝗗 position: $LLY Heavily 𝗕𝗢𝗢𝗦𝗧𝗘𝗗: $ABT & $ABBV 𝗥𝗲𝗱𝘂𝗰𝗲𝗱 by 80%: NVDA, SNDK & MU 𝗦𝗢𝗟𝗗 out: Astera Labs People don't like them but Citadel's 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗶𝘀 𝗨𝗣 93.26% in the past 3 years. Watch what they do. Source: hedgefollow.com/funds/Citadel+Advisors
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 3 at 9:15 PM
$SLS $ABBV $BMY Chart Since the IDMC UNBLINDED ACTUAL P3 DATA - says it all. "Select blinded data revealed that fewer than 50% of enrolled patients were confirmed deceased approximately 10 months after enrollment and an approximate median follow-up of 13.5 months (range, 1-36+). Additionally, pooled median survival appeared to be at least 13.5 months compared with an expected 6-month survival in a similar patient population. An additional blinded analysis of early immune response in a random sample of patients showed an 80% GPS-specific immune response rate. “The interim results represent a major step forward in the treatment of AML, offering hope for patients in remission,” Yair Levy, MD, director of Hematologic Malignancies Research at Texas Oncology Baylor University Medical Center. “I am very hopeful that we will see a new standard of care in treating [patients with] AML based on the outcomes we have observed in previous GPS trials.” open-label REGAL trial https://www.cancernetwork.com/view/galinpepimut-s-completes-phase-3-regal-interim-analysis-in-aml
0 · Reply
SellasgpsCurativeBAT11
SellasgpsCurativeBAT11 Sep. 3 at 6:41 PM
$ABBV $BMY $SLS Greg, last 2 patients to hit 80 Events is coming from GPS 48 Patients that are functionally CURED. Now that is why I have been saying that don’t be surprised if there is a halt for efficacy by IDMC. All things are possible here at this point in time.✌️🙏❤️‍🩹
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 3 at 6:40 PM
$SLS $ABBV $BMY Now is the time Don't wait until the Imminent 80th event pr and buy in for $25 - before this runs to $150 on the Gps P3 Top line: P3 TOP LINE • GPs MOS 36 months CR2 AML vs BAT < 10 months $MRNA Added $40B in a Day Based on a 13.7 Month MOS for 2L Melanoma • this Rigged $13.90 Share Price will be $139 and running as the market realizes GPs true value - treating 50,000 AML Remission Patients each year - and generating Tens of Billions of Dollars in Real Revenue.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 3 at 6:34 PM
$SLS $ABBV $BMY Tuesday - after the LONG Weekend - it'll 120 days - a full 4 Months, when we'd been seeing 1 event Per month. 4 Charts WT1+ Long Tail Survivors
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 3 at 5:51 PM
$SLS Jan 2025 REGAL Interim Analysis was announced -- 60 Events. $.9 / $1.0 share price at the time - Jumped to $1.70 Including 50M shares of Dilution. Mcap increased 3x ... in a week after the Interim. Added Cash / warrants.... • the Share PRICE Started Climbing - along with funds invested, cash on hand, BAT Phase 3 Trial Failures, Market cap up more than the Share Price. • ALL SINCE THE IDMC UNBLINDED ACTUAL PHASE 3 MOS and Confirmatory Immune Response DATA • that told Smarter Money than most of US -- GPS is reason we are seeing Miraculous Extended Survival. $ABBV $BMY who own Aza VEN - Know ... and many many others Holding the 200M share float. https://www.onclive.com/view/maintenance-galinpepimut-s-appears-effective-and-safe-in-aml-in-second-cr
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 3 at 3:53 PM
$SLS $MRNA $ABBV One of the Most Pertinent Published Trial Data Sets -- Confirming GPs is worth close to $50B to big pharma Look at the dismal survival . absent transplant . with BAT NEJM Randomized Paradigm AML Trial Confirming GPS is doing what its done in all Prior 7 Trials, including 2 Phase 2's for AML Remission - P3 Results are GOLDEN.... Gps is Getting FDA Approved - and SLS is worth Close to $50B the Instant the IMMINENT P3 Data is announced.
0 · Reply
focafoca99
focafoca99 Sep. 3 at 12:41 PM
$ABBV foresees a fireside chat at the Morgan Stanley Global Healthcare Conference on Sep 15. https://www.rapidticker.com/news/abbv-abbvie-to-present-at-the-086dfd
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 2 at 6:12 PM
$SLS $MRNA We have direct apples to apples MOS comparisons for GPS Immunotherapy and BAT in AML First Remission (CR1) Absent Transplant. • SOC for CR1 Remission Maintenance - Onureg /Aza MOS 24.7 Months • Onureg + VEN or Aza+VEN Trial Data / Dr. Kantarjian 19 months MOS • VIALE-A Aza+VEN Phase 3 Failed - $ABBV terminated the trial due to toxicity. GPs MOS was not yet reached > 67.6 months. vs 24.7 months +2 months for Treatment. vs 19 months real world results from Dr. Kantarjian et al., 114 days since the 78th event - while we await 2 events. 60th Dec 2024 72nd Dec 2025 78th MAY 2026 About 1 Event Per Month its been 114. I saw an idiot (sorrynot)/ long say the other day, it would be a great surprise to see the 80th Event PR AH today ... HOW THE F WOULD IT BE A SURPRISE ... Its BEEN 114 Days.... 3 months 24 days ... ANY DAY NOW
0 · Reply
Pope_of_Profit
Pope_of_Profit Sep. 2 at 5:35 PM
$ABBV my bet is this will go below (a) within a couple of days
0 · Reply
Mergerbrief
Mergerbrief Sep. 2 at 12:11 PM
$APGE / $ABBV expected to close today. No second request, no litigation, no activist, no drama. Announced, tendered, done. Not every deal needs a story. Some of them just pay you.
0 · Reply
YouVSYou
YouVSYou Sep. 2 at 3:51 AM
When investors leave high-growth risk assets, they often rotate into defensive giants like $JNJ, $MRK, $ABBV and $UNH, which is helping XLV $CLOV is an interesting viable wild card @Fibonacci5
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 1 at 7:42 PM
$SLS $ABBV $MRNA $XBI 78th EVENT MAY 11 Very Likely Once the 80th Event Occurs, the IDMC has Tabulated and Compiled all trial data up to the 79th event. So its adding 1 more event ... and we can get the Top Line Data similar to what $MRNA Disclosed MOS for Treatment and Control Arms. MRNA Drug 13.2 Month Median OS for the Treatment 7 months for Control added $40B to the Market cap in a day. Same thing or very similar is about to happen at SLS.
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Sep. 1 at 6:04 PM
$SLS 80,000 AML Patients Diagnosed each year 80% Obtain a First Remission (CR1) - Onureg is the SOC for CR1 Patients ineligible for Transplant (50%) Onureg aka Aza, MOS is 24.7 Months -- -- GPS Phase 2 MOS Not Reached > Greater than 67.6 Months GPS Phase 2 MOS in the SAME Exact First Remission (CR1) Transplant Ineligible Setting https://www.onuregpro.com/efficacy $ABBV Combined VEN - Venetoclax w Onureg in the VIALE-M Phase 3 trial - IT FAILED --- VIALE-M AML First Remission CR1 Maintenance Trial Failed. - 362 Patient Trial DATA for Aza+VEN in First Remission (CR1) w a MOS of 17.3 Months $MRNA - SLS is the NEXT MRNA $XBI
3 · Reply